These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 34921091)
1. Seroprevalence of SARS-CoV-2 in urban settings in three sub-Saharan African countries (SeroCoV): a study protocol for a household-based cross-sectional prevalence study using two-stage cluster sampling. Lorenz E; Souares A; Amuasi J; Loag W; Deschermeier C; Fusco D; Benke D; A Rakotoarivelo R; Rasamoelina MT; Rakotozandrindrainy R; Sie A; Afum-Adjei Awuah A; May J; Eibach D; Struck N BMJ Open; 2021 Dec; 11(12):e056853. PubMed ID: 34921091 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626 [TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India. Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA Front Public Health; 2022; 10():967447. PubMed ID: 36276377 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol. Sentís A; Torán P; Esperalba J; Agustí C; Ángel M; Fernández MG; Dopico E; Salvador-González B; González MV; Bordas A; Antón A; Violan C; Montoro-Fernández M; Aceiton J; Egea-Cortés L; Alonso L; Dacosta-Aguayo R; Calatayud L; Lejardi Y; Mendioroz J; Basora J; Reyes-Urueña J; Casabona J BMJ Open; 2022 Feb; 12(2):e053237. PubMed ID: 35140153 [TBL] [Abstract][Full Text] [Related]
11. A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy. Post LA; Argaw ST; Jones C; Moss CB; Resnick D; Singh LN; Murphy RL; Achenbach CJ; White J; Issa TZ; Boctor MJ; Oehmke JF J Med Internet Res; 2020 Nov; 22(11):e24248. PubMed ID: 33211026 [TBL] [Abstract][Full Text] [Related]
12. Morbidity and mortality burden of COVID-19 in rural Madagascar: results from a longitudinal cohort and nested seroprevalence study. Garchitorena A; Rasoloharimanana LT; Rakotonanahary RJ; Evans MV; Miller AC; Finnegan KE; Cordier LF; Cowley G; Razafinjato B; Randriamanambintsoa M; Andrianambinina S; Popper SJ; Hotahiene R; Bonds MH; Schoenhals M Int J Epidemiol; 2023 Dec; 52(6):1745-1755. PubMed ID: 37793001 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R; Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347 [TBL] [Abstract][Full Text] [Related]
14. Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: A descriptive cross-sectional study. Sana A; Djemaï E; De Vreyer P; Thivillon T; Badolo H; Berthé A; Kania D PLoS One; 2024; 19(8):e0305850. PubMed ID: 39110710 [TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country. Kaboré OD; Poda A; Ouattara CA; Michodigni FN; Belem AA; Sawadogo Y; Zoungrana J; Galal L; Meda CZ; Godreuil S; Ouédraogo AS PLoS One; 2023; 18(6):e0286665. PubMed ID: 37315090 [TBL] [Abstract][Full Text] [Related]
17. The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation. Ouedraogo S; Traoré IT; Kania D; Kaboré NF; Mamguem Kamga A; Badolo H; Yara M; Sanou G; Koné A; Kagoné ST; Ouédraogo E; Konaté B; Médah R; de Rekeneire N; Poda A; Diendere AE; Ouédraogo B; Billa O; Paradis G; Tinto H; Dabakuyo-Yonli TS Influenza Other Respir Viruses; 2023 Nov; 17(11):e13216. PubMed ID: 38019697 [TBL] [Abstract][Full Text] [Related]
18. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689 [TBL] [Abstract][Full Text] [Related]
19. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441 [TBL] [Abstract][Full Text] [Related]
20. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]